Lucatumumab
Monoclonal antibody / From Wikipedia, the free encyclopedia
Lucatumumab (CHIR 12.12 or HCD122)[1] is a human monoclonal antibody against CD40[2] development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.[3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD40 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Molar mass | 146 kg/mol |
![]() ![]() |
It is an antagonist to CD40 that was created by scientists at Chiron using Abgenix' XenoMouse transgenic mouse to generate fully human antibodies.[4][5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.[6][7][8] Novartis took over the project when it acquired Chiron in 2005.[9][10]
In in vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced cell lysis.[11]
Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.[1] The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.[1]